ARTICLE | Company News
Dara BioSciences, Innocutis sales and marketing update
April 2, 2012 7:00 AM UTC
Innocutis granted Dara exclusive, U.S. commercialization rights to Bionect 0.2% hyaluronic acid for cancer and radiation cancer indications. The low molecular weight formulation of hyaluronic acid is...